BRIEF-Syndax Pharmaceuticals Reports Q4 Financial Results
BRIEF-Syndax Pharmaceuticals Reports Q4 Financial Results
简介-Syndax制药公司报告第四季度财务业绩
March 8 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 8 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.44
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA
* END OF YEAR CASH BALANCE OF $293.1 MILLION PROVIDES CASH RUNWAY INTO 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月8日电-Syndax PharmPharmticals Inc：*Syndax PharmPharmticals报告2020年第四季度财务业绩，并提供临床和业务最新情况*第四季度每股亏损0.44美元*第四季度每股收益预估-0.49美元-REFINITIV IBES数据*年终现金余额2.931亿美元为进入2023年提供了现金跑道Eikon的源文本：进一步的公司报道：(Reurs.Briefs@thomsonreurs.com；)
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！